| 貨號(hào) | 規(guī)格 | 價(jià)格 | 上海 | 北京 | 武漢 | 南京 | 購(gòu)買數(shù)量 |
|---|---|---|---|---|---|---|---|
S81028-2mg |
99.2% | ￥200.00 | 5 | - | - | - |
|
S81028-5mg |
99.2% | ￥300.00 | 6 | - | - | - |
|
S81028-10mg |
99.2% | ￥420.00 | 6 | - | - | - |
|
S81028-25mg |
99.2% | ￥520.00 | 6 | - | - | - |
|
S81028-50mg |
≥99% | ￥960.00 | 貨期：2-3天 | - | - | - |
|
S81028-100mg |
≥99% | ￥1800.00 | 貨期：2-3天 | - | - | - |
|
GSK429286A is a selective inhibitor of ROCK1 with an IC50 value of 14 nM.
| 產(chǎn)品描述： | GSK429286A is a selective inhibitor of ROCK1 with an IC50 value of 14 nM. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點(diǎn)： | ROCK1:14 nM (IC50);RSK:780 nM (IC50);p70S6K:1940 nM (IC50);ROCK | ||||||||||||||||||||
| 體內(nèi)研究： | GSK429286A has 61% oral bioavailability in male Sprague-Dawley rats. Oral administration of GSK429286A at single doses of 3-30 mg/kg dramatically reduces mean arterial pressure in the spontaneously hypertensive rats (SHRs) in a dose-dependent manner, with a maximum decrease of 50 mmHg after approximately 2 hours treatment at dose of 30 mg/kg | ||||||||||||||||||||
| 參考文獻(xiàn)： | 1. Goodman KB et al Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. J Med Chem. 2007 Jan 11;50(1):6-9. 2. Nichols RJ et al Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J. 2009 Oct 23;424(1):47-60. | ||||||||||||||||||||
| 溶解性： | DMSO : ≥ 51 mg/mL (117.95 mM) | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號(hào)
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
掃一掃關(guān)注上海源葉微信公眾號(hào)
北京